<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03918239</url>
  </required_header>
  <id_info>
    <org_study_id>SHP643-102</org_study_id>
    <nct_id>NCT03918239</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Parallel-arm, Single-center, Phase 1 Study to Determine the Bioavailability of Lanadelumab Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate bioavailability of lanadelumab (SHP643) following a
      single, 2 milliliter (mL) subcutaneous (SC) dose of 300 milligrams (mg) delivered by
      prefilled syringe (PFS) or auto injector (AI) in healthy adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Actual">November 13, 2019</completion_date>
  <primary_completion_date type="Actual">November 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) in Plasma</measure>
    <time_frame>Pre-dose, 8, 24, 48, 72, 96, 168, 336, 504, 672, 1008, 1344, 2016, 2688 hours post dose</time_frame>
    <description>AUC0-last of SHP643 will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-Inf) of SHP643 in Plasma</measure>
    <time_frame>Pre-dose, 8, 24, 48, 72, 96, 168, 336, 504, 672, 1008, 1344, 2016, 2688 hours post dose</time_frame>
    <description>AUC0-Inf of SHP643 will be assessed based on the predicted concentration at Tlast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Drug Concentration (Cmax) of SHP643 in Plasma</measure>
    <time_frame>Pre-dose, 8, 24, 48, 72, 96, 168, 336, 504, 672, 1008, 1344, 2016, 2688 hours post dose</time_frame>
    <description>Cmax of SHP643 will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Time to Reach (Tmax) in Maximum Observed Plasma Drug Concentration of SHP643</measure>
    <time_frame>Pre-dose, 8, 24, 48, 72, 96, 168, 336, 504, 672, 1008, 1344, 2016, 2688 hours post dose</time_frame>
    <description>Tmax of SHP643 will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-Life (T1/2) of SHP643 in Plasma</measure>
    <time_frame>Pre-dose, 8, 24, 48, 72, 96, 168, 336, 504, 672, 1008, 1344, 2016, 2688 hours post dose</time_frame>
    <description>T1/2 of SHP643 will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance for Extravascular Administration Divided by the Fraction of Dose Absorbed (CL/F) of SHP643 in Plasma</measure>
    <time_frame>Pre-dose, 8, 24, 48, 72, 96, 168, 336, 504, 672, 1008, 1344, 2016, 2688 hours post dose</time_frame>
    <description>CL/F of SHP643 will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution Associated with the Terminal Slope Following Extravascular Administration Divided by the Fraction of Dose Absorbed (Vdz/F) of SHP643 in Plasma</measure>
    <time_frame>Pre-dose, 8, 24, 48, 72, 96, 168, 336, 504, 672, 1008, 1344, 2016, 2688 hours post dose</time_frame>
    <description>Vdz/F of SHP643 will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First Order Rate Constant Associated with the Terminal (log-linear) Portion of the Curve (Lambda-z) of SHP643 in Plasma</measure>
    <time_frame>Pre-dose, 8, 24, 48, 72, 96, 168, 336, 504, 672, 1008, 1344, 2016, 2688 hours post dose</time_frame>
    <description>Lambda-z of SHP643 will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From start of study treatment up to Day 112 continuously monitored throughout the study</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs (TEAEs) are defined as AEs with start dates or worsening dates at the time of or following the first exposure to investigational product. The TEAEs will be further categorized based on severity as mild (may require only minimal treatment) to severe (may require intensive therapeutic intervention).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Developed Antidrug Antibodies (ADA) to SHP643</measure>
    <time_frame>Day 1, 14, 28, 56 and 112</time_frame>
    <description>Number of participants with presence of antidrug antibodies to SHP643 will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>SHP643 Prefilled Syringe (PFS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 300 milligram (mg) of SHP643 PFS Subcutaneous (SC) injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHP643 Autoinjector (AI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 300 mg of SHP643 AI SC injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP643</intervention_name>
    <description>Participants will receive injection of SHP643.</description>
    <arm_group_label>SHP643 Autoinjector (AI)</arm_group_label>
    <arm_group_label>SHP643 Prefilled Syringe (PFS)</arm_group_label>
    <other_name>DX-2930 (formerly)</other_name>
    <other_name>Lanadelumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

          -  Ability to voluntarily provide written, signed, and dated informed consent to
             participate in the study.

          -  Age 18-55, inclusive, at the time of consent. The date of signature of the informed
             consent is defined as the beginning of the screening period. This inclusion criterion
             will only be assessed at the first screening visit.

          -  Male, or non-pregnant, non-lactating female who agrees to comply with any applicable
             contraceptive requirements of the protocol or females of non-childbearing potential.

          -  Must be considered &quot;healthy&quot;, per the investigator. Healthy status is defined by
             absence of evidence of any active or chronic disease following a detailed medical and
             surgical history, a complete physical examination including vital signs, 12-lead
             electrocardiogram (ECG), hematology, blood chemistry, and urinalysis.

          -  Body mass index between 18.5-33 kilogram per square meter (kg/m^2), inclusive, with a
             body weight greater than or equal to (&gt;=) 45 kilogram (kg) (99 pounds [lbs]). This
             inclusion criterion will only be assessed at the screening visit and on Day -1.

          -  Willing and able to consume standardized meals during the confinement period of the
             study.

          -  All participants will be required to consume the identical meals on study days when
             serial PK blood samples are collected

        Exclusion Criteria:

          -  Per the investigator, a history of any hematological, hepatic, respiratory,
             cardiovascular, renal, neurological or psychiatric disease, gall bladder removal, or
             current or recurrent disease that could affect the action, absorption, or disposition
             of the investigational product, or clinical or laboratory assessments.

          -  Per the investigator, a current or relevant history of physical or psychiatric
             illness, any medical disorder that may require treatment or make the participant
             unlikely to complete the study, or any condition that present's undue risk from the
             investigational product or procedures.

          -  Known or suspected intolerance or hypersensitivity to the investigational product,
             closelyrelated compounds, or any of the stated ingredients.

          -  Significant illness, as judged by the investigator, within 2 weeks of the dose of
             investigational product.

          -  Known history of alcohol or other substance abuse within the last year, per the
             investigator.

          -  Donation of blood or blood products (e.g. plasma or platelets) within 60 days prior to
             receiving the dose of investigational product.

          -  Within 30 days prior to the dose of investigational product.

               1. Have used an investigational product (if elimination half-life is &lt;6 days,
                  otherwise 5 half lives).

               2. Have been enrolled in a clinical study (including vaccine studies) that, in the
                  investigator's opinion, may impact this Shire-sponsored study.

          -  Confirmed systolic blood pressure (BP) &gt;139 millimeters of mercury (mmHg) or &lt;89 mmHg,
             and diastolic BP &gt;89 mmHg or &lt;49 mmHg.

          -  Twelve-lead ECG values demonstrating QTcF &gt;450 milliseconds (msec) (males) or &gt;470
             msec (females) at the screening visit or Day -1. If QTcF exceeds 450 msec (males) or
             470 msec (females), the ECG should be repeated 2 more times and the average of the 3
             QTcF values should be used to determine the participants eligibility.

          -  Positive screen for drugs of abuse and/or disallowed drugs (i.e. amphetamines,
             benzodiazepines, barbiturates, cocaine, opiates, phencyclidine) at screening, or drugs
             of abuse or alcohol on Day -1. This screen will include marijuana.

          -  Male participants who consume more than 21 units of alcohol per week or 3 units per
             day. Female participants who consume more than 14 units of alcohol per week or 2 units
             per day. One alcohol unit=1 beer or 1 wine (5 ounces [oz) per 150 milliliter [mL]) or
             1 liquor (1.5 oz/40 mL) or 0.75 oz alcohol.

          -  Positive human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or
             hepatitis C virus (HCV) antibody screen.

          -  Use of tobacco in any form (e.g. smoking or chewing) or other nicotine-containing
             products in any form (e.g. gum, patch, electronic). Ex-users must report that they
             have stopped using tobacco for at least 30 days prior to receiving the dose of
             investigational product.

          -  Routine consumption of more than 2 units of caffeine per day or participants who
             experience caffeine withdrawal headaches. One caffeine unit is contained in the
             following items: one 6 oz (180 ml) cup of coffee, two 12 oz (360 ml) cans of cola, one
             12 oz cup of tea, and three 1 oz (85 g) chocolate bars. Decaffeinated coffee, tea, or
             cola are not considered to contain caffeine).

          -  Current use of any medication (including over-the-counter, herbal, or homeopathic
             preparations; with the exception of stable hormonal replacement therapy or hormonal
             contraceptives). Current use is defined as use within 14 days of the dose of
             investigational product. (Prior and Concomitant Treatment) for a list of permitted
             medications.

          -  Abnormal laboratory values considered clinically significant, as determined by the
             investigator, at screening or Day -1.

          -  History of any clinically significant surgery or procedure within 8 weeks of receiving
             the dose of investigational product, as determined by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

